Key Points
- Urogen General Counsel Jason Drew Smith sold 7,479 shares on Feb. 3 at an average price of $19.69 for $147,261.51, leaving him with 51,326 shares and a 12.72% reduction in his ownership.
- UroGen is a nearly $990 million market-cap biotech (one‑year range $3.42–$30.00) with a MarketBeat consensus of "Moderate Buy" (average target $33.00; seven Buys, one Hold, one Sell).
- Institutional ownership is high at 91.29%, with recent sizable inflows — notably AQR boosted its stake by 347.5% to 114,066 shares and Jane Street nearly doubled its position.
Urogen Pharma (NASDAQ:URGN - Get Free Report) General Counsel Jason Drew Smith sold 7,479 shares of the stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $19.69, for a total transaction of $147,261.51. Following the completion of the sale, the general counsel owned 51,326 shares in the company, valued at $1,010,608.94. This represents a 12.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Urogen Pharma Price Performance
URGN opened at $21.14 on Thursday. The firm has a market capitalization of $989.56 million, a P/E ratio of -6.11 and a beta of 1.32. Urogen Pharma has a one year low of $3.42 and a one year high of $30.00. The company has a fifty day moving average price of $21.71 and a 200-day moving average price of $20.73.
Institutional Inflows and Outflows
Several large investors have recently modified their holdings of the stock. AQR Capital Management LLC grew its position in shares of Urogen Pharma by 347.5% in the 1st quarter. AQR Capital Management LLC now owns 114,066 shares of the company's stock worth $1,262,000 after buying an additional 88,577 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Urogen Pharma by 7.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,320 shares of the company's stock worth $258,000 after acquiring an additional 1,653 shares during the period. Jane Street Group LLC boosted its holdings in Urogen Pharma by 94.3% in the first quarter. Jane Street Group LLC now owns 51,177 shares of the company's stock valued at $566,000 after acquiring an additional 24,839 shares in the last quarter. Truist Financial Corp bought a new stake in Urogen Pharma in the second quarter valued at $423,000. Finally, Allianz Asset Management GmbH purchased a new position in Urogen Pharma during the 2nd quarter valued at $203,000. Hedge funds and other institutional investors own 91.29% of the company's stock.
Wall Street Analyst Weigh In
A number of equities research analysts recently weighed in on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Urogen Pharma in a research note on Wednesday, January 21st. HC Wainwright reiterated a "buy" rating and issued a $40.00 target price on shares of Urogen Pharma in a research report on Monday, October 27th. D. Boral Capital reaffirmed a "buy" rating and set a $33.00 price target on shares of Urogen Pharma in a research note on Friday, January 23rd. Finally, Wall Street Zen upgraded Urogen Pharma from a "sell" rating to a "hold" rating in a report on Saturday, November 8th. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $33.00.
Read Our Latest Stock Report on Urogen Pharma
About Urogen Pharma
(
Get Free Report)
UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra'anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.
The company's lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
